References
- Rossouw J E, Anderson G L, Prentice R, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321–333
- Rossouw J E, Prentice R L, Manson J E, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465–1477
- Manson J E, Allison M A, Rossouw J E, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007; 356: 2591–2602
- Collins P, Rosano G, Casey C, et al. Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists. Eur Heart J 2007; 28: 2028–2040
- Lobo R. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. Arch Intern Med 2004; 164: 482–484
- Grodstein F, Manson J E, Stampfer M J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health 2006; 15: 35–44
- Hendrix S L, Wassertheil-Smoller S, Johnson K C, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006; 113: 2425–2434
- Grodstein F, Manson J E, Stampfer J, Rexrode K. Postmenopausal hormone therapy and stroke. The role of time since menopause and age of initiation of hormone therapy. Arch Intern Med 2008; 168: 861–866
- Cushman M, Kuller L H, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 1573–1580
- Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840–845